Log in or Sign up for Free to view tailored content for your specialty!
Hepatitis C News
HCV drugs sofosbuvir, daclatasvir show promise as potential COVID-19 treatment
Using hepatitis C drugs sofosbuvir and daclatasvir in combination with standard care to treat patients with COVID-19 resulted in better 14-day recovery rates and a shorter hospital stay, according to data presented at AIDS 2020.
Survey: PCPs need greater hepatitis B vaccination awareness
Primary care physicians do not realize how low the rate of adult hepatitis B vaccination is in the United States, according to a small survey.
Log in or Sign up for Free to view tailored content for your specialty!
HHS updates transplant guidance to improve safety, access to organs
The HHS and the U.S. Public Health Service updated the solid organ transplant guidance to evaluate donors and monitor recipients for HIV, hepatitis B virus, and hepatitis C virus infections, according to a release.
Sexual risk behavior influences HCV reinfection incidence among HIV-positive MSM
High rates of hepatitis C virus reinfection strongly correlated with risky sexual behavior among men who have sex with men who are HIV-positive, according to data published in Clinical Infectious Diseases.
Opioid agonist therapy increases linkage to HCV care among PWID
Opioid agonist therapy can increase linkage to hepatitis C virus care among people who inject drugs, or PWID, according to a systematic review in Clinical Infectious Diseases.
Cost-effective drug found to prevent hepatitis C transmission in kidney transplantation
A short course of direct-acting anti-viral prophylaxis may be effective in preventing transmission of hepatitis C virus from kidney donors to recipients, according to study results presented virtually at the American Transplant Congress.
VIDEO: Treating liver diseases during COVID-19
In this exclusive video, Nancy S. Reau, MD, section chief of hepatology and associate director of organ transplantation at Rush University Medical Center, discusses some important aspects of treating liver diseases during the COVID-19 pandemic.
Universal screening reveals ‘striking’ HCV antibody prevalence in people born after 1965
Universal hepatitis C virus screening in EDs with the ability to opt out showed that nearly half of infections were identified in people born after 1965, according to findings published in MMWR.
HCV treatment through telehealth highly effective regardless of DAA regimen
Using the American Association for the Study of Liver Diseases and Infectious Diseases Society of America guidelines, treatment for HCV in the Department of Corrections through telehealth was highly effective with an overall sustained virologic response of 97%, regardless of underlying genotype or direct-acting antivirals regimen used, according to data from Digestive Disease Week.
FDA approves Epclusa for pediatric HCV
Epclusa is now available for the treatment of children with any of the six genotypes of hepatitis C virus after obtaining approval from the FDA, according to a press release.
-
Headline News
A potential new paradigm for treating acute migraine: Timolol nasal spray
November 15, 20245 min read -
Headline News
AI-enabled video of skin on face, hands may detect high blood pressure, diabetes
November 15, 20242 min read -
Headline News
‘Troubling’ data show lack of awareness about lung cancer screening
November 15, 20242 min read
-
Headline News
A potential new paradigm for treating acute migraine: Timolol nasal spray
November 15, 20245 min read -
Headline News
AI-enabled video of skin on face, hands may detect high blood pressure, diabetes
November 15, 20242 min read -
Headline News
‘Troubling’ data show lack of awareness about lung cancer screening
November 15, 20242 min read